OC
XLRN

Oppenheimer & Co’s Acceleron Pharma XLRN Stock Holding History

Oppenheimer & Co’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-6,817
Closed -$289K – 1409
2017
Q4 		$289K Buy
6,817
+786
+13% +$29.5K 0.01% 1071
2017
Q3 		$225K Buy
+6,031
New +$209K 0.01% 1144

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Oppenheimer & Co's XLRN Position: Q1 2018 in Review

Oppenheimer & Co sold out of Acceleron Pharma (XLRN) in Q1 2018, closing a stake of 6,817 shares — an estimated $289K sold.

Oppenheimer & Co first reported a position in XLRN in Q3 2017 and held it in 2 quarters. The position peaked at $289K in Q4 2017. 150 funds tracked by Wall St. Rank hold XLRN as of Q1 2018.

  • Oppenheimer & Co reported no remaining Acceleron Pharma position as of Q1 2018 after selling out during the quarter.
  • Oppenheimer & Co sold 6,817 Acceleron Pharma shares in Q1 2018, an estimated $289K.
  • Oppenheimer & Co first reported a position in Acceleron Pharma in Q3 2017 and held it in 2 quarters.
  • Oppenheimer & Co's Acceleron Pharma position peaked at $289K in Q4 2017.
  • 150 funds tracked by Wall St. Rank held Acceleron Pharma as of Q1 2018.

Based on Oppenheimer & Co's 13F filing for Q1 2018, filed 1 May 2018.